subscribe
 

Protomold - A shot in the arm for next generation diagnostics

Bacterial endotoxin contamination is an issue all medical device manufacturers need to be aware of. Clinical implants, and all vaccines and...

Promising pre-clinical data in Cystic Fibrosis for ProtAffin AG’s PA401 to be presented at ATS, Philadelphia, 17-22 May 2013

ProtAffin AG has announced that a collaboration with a leading European centre for the study of cystic fibrosis has generated promising pre-clinical results for the company’s lead anti-inflammatory product, PA401.

Almac to deliver insight into Supply Chain Management at Clinical Trial Supply Europe Event

Almac, leading provider of contract services to the global Pharmaceutical and Biotech industries, will play a key role in delivering industry insight on the topic of Supply Chain Management at this year’s 14th Annual CTS Europe event,...

Nano-machines for 'Bionic Proteins'

Physicists of the University of Vienna together with researchers from the University of Natural Resources and Life Sciences Vienna developed...

Prosthetics study to improve mobility of amputees

Research by the University of Salford, University of Manchester and prosthetics company Blatchford’s Endolite Technology Centre will help to enhance the mobility of people with above-knee amputations by improving the energy efficiency of...

Patent changes - who will lose and who will gain?

Is the European unitary patent protection system equally harmful for SME of whole Central Europe? Find out at the 12th edition of the biggest CE innovative biobusiness affairs – BioForum, held in Budapest from 22nd to 23rd of May 2013.

Pharmapack Europe 2013

On 13 & 14 February 2013, the healthcare industry’s major players will meet for the occasion of the 12th edition of Pharmapack Europe in...

Almac launches US commercial packaging operations with successful FDA inspection

Almac has announced the successful inspection of its new US Commercial Packaging operations located in Audubon, PA by the Food and Drug Administration (FDA).

Prosensa achieves orphan drug status on its entire Duchenne muscular dystrophy portfolio

Prosensa has achieved orphan drug designation in the EU and the US for all of its compounds for the treatment of Duchenne muscular dystrophy (DMD).

New salmon peptone – sustainable marine resources used in the production of high-value biotech products

A project has successfully examined the commercial viability of the use of marine derived peptones in the production of high value products...

New treatment could combat deadly chemical agents

An enzyme treatment which could neutralise the effects of lethal chemicals responsible for the deaths of hundreds of thousands of people...

Fleming Europe's Global SFE Forum 2013

Identifying and addressing physicians' differing views on the 'right experience' has become one of the top priorities for pharma & biotech companies implementing new commercial models. Find out more at the Global SFE Forum in Amsterdam on ...

Antibiotics based on a new principle may defeat MRSA

Scientists at Karolinska Institutet in Sweden have presented a new principle for fighting bacterial infections, in other words, a new type of antibiotic, in the medical journal FASEB. The new antibiotic mechanism is based on selectively...

Roche and IMI promote use of stem cell technology to enhance drug development

Roche and the Innovative Medicines Initiative have announced the launch of StemBANCC, a new academic–industry partnership that unites ten pharmaceutical companies and 23 academic institutions.

New study shows how copper restricts the spread of global antibiotic-resistant infections

New research from the University of Southampton has shown that copper can prevent horizontal transmission of genes, which has contributed to the increasing number of antibiotic-resistant infections worldwide.

New Queen’s University plasma jet gives ‘cold’ shoulder to superbugs

Scientists at Queen’s University Belfast have developed a new technique which has the potential to kill off hospital superbugs like Pseudomonas aeruginosa, C. difficile and MRSA.

8th Annual Quality & OPEX in Pharma & Biotech

Leading pharma players such as Pfizer, Roche, Sanofi, Merck, Novartis, Genzyme, Teva, etc. understand that manufacturing quality is becoming a key driver in successful and timely product launches. Find solutions to overcome the challenges...

Reversible oxygen-sensing ‘switching’ mechanism discovered

Bacteria that cause disease in humans have a ‘reversible switching mechanism’ that allows them to adapt to environments lacking oxygen, scientists at the University of East Anglia (UEA) have found.

New bacteria resistant materials discovered

Using state-of-the-art technology scientists at The University of Nottingham have discovered a new class of polymers that are resistant to bacterial attachment. These new materials could lead to a significant reduction in hospital...

Portable system for aspiration and disposal of biological waste

The VACUSIP from INTEGRA provides an ideal benchtop solution for the safe aspiration and disposal of small volumes of liquid waste in...

Pages

Newsbrief

FREE NEWSBRIEF SUBSCRIPTION

To receive the Scientist Live weekly email NewsBrief please enter your details below

Twitter Icon © Setform Limited
subscribe